Admin supplement for The University of Iowa's Regional Stroke Research Network

项目摘要/摘要 爱荷华大学区域协调卒中中心(UIRCC)的理想定位是 开发、推广并高效地进行高质量、多地点的中风临床试验 预防、治疗和康复，与NIH StrokeNet的总体目标一致。这个 爱荷华大学(UI)是唯一的学术医疗机构和综合性中风中心 在这个州。印第安纳大学领导并参与了具有里程碑意义的脑血管临床试验 疾病超过50年，如组织10172在急性中风治疗(TOAST)研究， 美国国立卫生研究院卒中量表和TOAST卒中亚型分类。在过去的10年里， UI一直担任UIRCC的角色，将我们多学科、尖端、 脑血管研究。我们通过成为顶尖人才展示了我们招收病人的能力。 首次StrokeNet试验的参与者，FUSE-3，并吸引了来自 上中西部--该地区在入学方面经历了独特的地理障碍。这个 UIRCC致力于缓解这种不可接受的差距。我们致力于从整体上 通过增加有效改善的中风干预措施的数量来扩大中风护理 患者结果，并通过扩大可从中受益的患者数量 干预措施。我们坚定地承诺继续成为StrokeNet的富有成效的成员。我们的 第一个目标是进一步推动红新月会成为一个高效和适应性强的基础设施，以招募 来自上中西部的病人。重组后的UIRCC包括八个准备好的试用 地理位置相连的医院将高效地进行关键试验并提供访问 患者生活在来自7个州的119个县，其中56%居住在农村邮政编码和 传统上由于地理障碍而被排除在试验之外。它还包括一个 大量未得到充分服务的美洲原住民。我们的第二个目标是继续发展 创新干预措施，扩大卒中护理。我们计划复制我们的尿酸成功 STORE，第一种成功通过NIH卒中临床前评估的脑保护剂 网络(SPAN)。我们的小组现在将领导尿酸测试通过新的 StrokeNet血栓切除术血管内平台(STEP)。我们将继续在我们的 多学科研究基础设施，调查人员和受训人员的多样化群体。这 包括UI SPAN翻译团队，以及临床研究人员和行业合作伙伴。 该基础设施将继续利用专门的用户界面试点资金来推动 干预措施，重点是那些简单的，因此广泛适用于 地理上不同的患者群体。

Project Summary/Abstract The University of Iowa Regional Coordinating Stroke Center (UIRCC) is ideally positioned to develop, promote, and efficiently conduct high-quality, multi-site clinical trials on stroke prevention, treatment, and recovery, in line with the overarching goal of the NIH StrokeNet. The University of Iowa (UI) is the only academic medical institution and comprehensive stroke center in the state. The UI has led and participated in landmark clinical trials in cerebrovascular disease for over 50 years such as the Org 10172 in Acute Stroke Treatment (TOAST) study, the NIH Stroke Scale and the TOAST classification of stroke subtype. Over the past 10 years, the UI has served as the UIRCC, bringing together our tradition of multidisciplinary, cutting-edge, cerebrovascular research. We demonstrated our ability to recruit patients by becoming the top enroller in the first StrokeNet trial, DEFUSE-3, and attracting a diverse patient population from the Upper Midwest—a region that experiences unique geographic barriers for enrollment. The UIRCC is committed to mitigating this unacceptable disparity. We are committed to holistically expanding stroke care by increasing the number of stroke interventions that effectively improve patient outcomes, and by expanding the number of patients who can benefit from such interventions. We have a strong commitment to remain a productive member of StrokeNet. Our first aim is to further advance the UIRCC as an efficient and adaptive infrastructure to recruit patients from the Upper Midwest. The restructured UIRCC comprises eight trial-ready geographically linked hospitals that will efficiently conduct critical trials and provide access to patients living in 119 counties from seven states, 56% of whom reside in rural zip codes and traditionally have been excluded from trials due to geographic barriers. It also includes a significant underserved Native American population. Our second aim is to continue to develop innovative interventions to expand stroke care. We plan to reproduce our uric acid success story, the first cerebroprotectant to succeed through the NIH Stroke Preclinical Assessment Network (SPAN). Our group will now be leading the testing of uric acid through the new StrokeNet Thrombectomy Endovascular Platform (STEP). We will continue to build on our multidisciplinary research infrastructure, a diverse group of investigators and trainees. This includes the UI SPAN translational team, as well as clinical researchers and industry partners. This infrastructure will continue to leverage dedicated UI pilot funds to ignite the development of interventions, with an emphasis on those that are simple and therefore widely applicable to a geographically diverse groups of patients.